Edwards Lifesciences (NYSE: EW) reported Q1 EPS of $0.66, $0.02 better than the analyst estimate of $0.64. Revenue for the quarter came in at $1.6 billion versus the consensus estimate of $1.58 billion.

GUIDANCE:

Edwards Lifesciences sees Q2 2024 EPS of $0.67-$0.71, versus the consensus of $0.64. Edwards Lifesciences sees Q2 2024 revenue of $1.62-1.7 billion, versus the consensus of $1.645 billion.

Edwards Lifesciences sees FY2024 EPS of $2.70-$2.80, versus the consensus of $2.75. Edwards Lifesciences sees FY2024 revenue of $6.3-6.6 billion, versus the consensus of $6.517 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.